InvestorsHub Logo

TPX

Followers 0
Posts 40567
Boards Moderated 4
Alias Born 10/24/2013

TPX

Re: None

Wednesday, 07/26/2017 2:14:03 PM

Wednesday, July 26, 2017 2:14:03 PM

Post# of 245502
$MCET Fatigue Pipeline Landscape with Latest Therapeutic Assessment Reviewed in H2 2017

VIDEO: http://u.wn.com/2017/07/26/Fatigue_Pipeline_Landscape_with_Latest_Therapeutic_Assessmen/

Albany, New York, July 26, 2017: Fatigue among training doctors is a serious public health concern; both for the health of the junior doctor and patients under their responsibility. Analysts have studied that 10% of people all around the world at any one time are suffering from persistent tiredness which could lead to mental distress. Due to this, treatment for fatigue is necessary. Market Research Hub (MRH) has recently broadcasted the latest study to its vast repository, which is titled as “Fatigue - Pipeline Review, H2 2017” and offers comprehensive information on the therapeutic under development for fatigue and overall pipeline landscape. The pipeline products described in this report have been analyzed on the basis of their development stage i.e. from pre-registration to discovery.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230567

The first section of the report presents an overview of fatigue (central nervous system). This section highlights the development of therapeutics, pipeline products utilized in fatigue and a comparative analysis of these pipeline products. Fatigue, which is characterized by a state of awareness of a range of sickness, is usually associated with mental or physical weakness, or both. It is often accompanied by a peculiar sense of discomfort, a desire to rest, and a decline in motivation referred to as fatigue sensation.

As per the findings, more cases of fatigue have a mental than physical cause, according to collected data. Major signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite. There are so many causes of fatigue that pinpointing the exact cause can sometimes be long and scrutinizing. In addition to aspects of daily life, prescription medications and diseases, conditions and sicknesses both physical and psychological can cause symptoms of fatigue.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/fatigue-pipeline-review-h2-2017-report.html

Moreover, the analysts have conducted an assessment of fatigue therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Drugs such as anamorelin hydrochloride, MRZ-9547, CTDP-001, BLI-1402, (lofepramine hydrochloride + phenylalanine), Caffeine and phenylbutyrate are studied in the report. With many new fatigue drugs in the pipeline, the market is expected to grow smoothly in the coming years.

Also, the therapeutics still under development by both universities and companies, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases have been presented. For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for fatigue. At present, key players involved in the therapeutic development are Aoxing Pharmaceutical Company Inc, Merz Pharma GmbH & Co KgaA. MultiCell Technologies Inc, BioLite Inc and Chronos Therapeutics Ltd.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.